CFS & Fibromyalgia Fibromyalgia Medical Marijuana for Fibromyalgia By Adrienne Dellwo Updated on June 05, 2022 Medically reviewed by Riteesha G. Reddy, MD Print Medical marijuana is a controversial issue—socially, legally, and politically. However, scientific evidence continues to mount suggesting that it could be a safe and effective treatment for numerous pain conditions, including fibromyalgia. We have some synthetic versions of tetrahydrocannabinol (THC) on the market, which is the substance associated with the "high" of marijuana. Studies suggest, though, that other compounds in the plant may have therapeutic value as well. Before discussing the specific effects of medical marijuana on fibromyalgia, it helps to know a little about something called the endogenous cannabinoid, or endocannabinoid, system. Catherine Lamothe-Sauvé / EyeEm / Getty Images What Is the Endocannabinoid System? "Endogenous" refers to something that originates from inside your body—something that's naturally there. "Cannabinoid" comes from the word cannabis, which is the technical name of the marijuana plant and refers to parts of your body that react to cannabis. We all have natural cannabinoids in our body, and more can be introduced by smoking or ingestion of marijuana or synthetic versions of it. The endocannabinoid system is involved in multiple processes, many of which are known or theorized to be impaired in fibromyalgia. These include: Energy metabolismImmune functionMemoryPain processingSleepStress responseTemperature regulationThe autonomic nervous system A 2004 paper on the endocannabinoid system proposed that fibromyalgia, irritable bowel syndrome, and related conditions be classified as "clinical endocannabinoid deficiency syndromes." It also cites research implicating problems with this symptom in schizophrenia, multiple sclerosis, Huntington's disease, some cases of Parkinson's disease, some cases of anorexia, and chronic motion sickness. The growing body of research suggesting that fibromyalgia may involve a deficit in endocannabinoids raises an obvious question: does increasing the amount of cannabinoids in the body help improve function and reduce symptoms? If so, what symptoms would medical marijuana (or synthetic equivalents) help alleviate? What the Research Says A 2014 review of research on marijuana for treating fibromyalgia, as well as the related conditions irritable bowel syndrome and migraine, suggested: Endocannabinoid deficiencies play a role in these conditionsMarijuana has the ability to block mechanisms of spinal, peripheral and gastrointestinal painClinical experience corroborates these findings Studies suggest that marijuana can significantly: Reduce pain (including nociceptive pain, which is a component of fibromyalgia)Reduce stiffnessLower inflammation (including myofascial inflammation, which may play a role in fibromyalgia)Enhance relaxationIncrease sleepinessIncrease feelings of well-being One study also saw that cannabis users had a significantly higher mental health score than non-users. Another one, which looked at the effect of a synthetic cannabinoid called nabilone, suggests that a low dose at night can improve sleep in fibromyalgia and can be considered an alternative to the popular antidepressant amitriptyline. A 2012 study looked at the prevalence of marijuana use in fibromyalgia. Researchers found that about 13% of participants were using the drug to help relieve their symptoms. Of these, more than 80% were using it illegally. Researchers also discovered that marijuana use was more likely in fibromyalgia patients with unstable mental illness. The relationship between marijuana use and mental illness in this group isn't known. Marijuana use also was more prevalent among men, unemployed participants, and those receiving disability payments. Side Effects A 2011 review stated that cannabinoids appear safe and were associated with mild or moderate side effects that were generally well tolerated, and that the drop-out rate due to side effects was low. Reported side effects included: DizzinessNauseaDry mouthAtaxia (reduced control of bodily movements) However, a 2014 study points out that we need longer-term studies in order to know what the long-term adverse effects could be, as well as the potential risks of misuse and addiction. Marijuana-Based Treatments Some synthetic forms of marijuana are on the market in the U.S. These drugs include: Marinol (dronabinol)Cesamet (nabilone) Medical marijuana is legal in several states. This form of the drug can be smoked, eaten (such as in baked goods), or vaporized. Eaten or vaporized forms may be safer and easier for some people to tolerate. Because of its accessibility as a recreational drug, some people opt to self-treat with marijuana illegally. This comes with its own risks, including: Being arrested, charged and convicted of a crimeReceiving marijuana with potentially dangerous substances includedReceiving a substandard product People using marijuana illegally may also be reluctant to tell their healthcare providers about it. This can lead to problems with drug interactions or, in case of a severe negative reaction, cause healthcare providers to misdiagnose the issue. For your own safety, you should always inform your healthcare provider and pharmacist about all drugs you are taking. CBD oil is also an option for those looking to treat fibromyalgia without the psychoactive properties of THC. Other Endocannabinoid System Treatments Research suggests that many other drugs, both prescription and over-the-counter, affect the endocannabinoid system. These include: Painkillers (acetaminophen, NSAIDs, opioids, glucocorticoids) Antidepressants (amitriptyline, duloxetine) Antipsychotics Anxiety drugs Anti-seizure drugs (pregabalin, gabapentin) Non-drug treatments that may also be effective include: MassageMyofascial manipulationAcupunctureSupplementsHerbal medicines Lifestyle factors including diet and exercise may also lead to changes in the endocannabinoid system. As with any treatment or management approach, you should talk to your healthcare provider about what the best options are for you. 17 Sources Verywell Health uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read our editorial process to learn more about how we fact-check and keep our content accurate, reliable, and trustworthy. Sagy I, Bar-Lev Schleider L, Abu-Shakra M, Novack V. Safety and Efficacy of Medical Cannabis in Fibromyalgia. J Clin Med. 2019;8(6):807. Published 2019 Jun 5. doi:10.3390/jcm8060807 Atakan Z. Cannabis, a complex plant: different compounds and different effects on individuals. Ther Adv Psychopharmacol. 2012;2(6):241–254. doi:10.1177/2045125312457586 Zou S, Kumar U. Cannabinoid Receptors and the Endocannabinoid System: Signaling and Function in the Central Nervous System. Int J Mol Sci. 2018;19(3):833. Published 2018 Mar 13. doi:10.3390/ijms19030833 Donvito G, Nass SR, Wilkerson JL, et al. The Endogenous Cannabinoid System: A Budding Source of Targets for Treating Inflammatory and Neuropathic Pain. Neuropsychopharmacology. 2018;43(1):52–79. doi:10.1038/npp.2017.204 Russo EB. Clinical endocannabinoid deficiency (CECD): can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions?. Neuro Endocrinol Lett. 2004;25(1-2):31-9. Russo EB. Clinical Endocannabinoid Deficiency Reconsidered: Current Research Supports the Theory in Migraine, Fibromyalgia, Irritable Bowel, and Other Treatment-Resistant Syndromes. Cannabis Cannabinoid Res. 2016;1(1):154–165. Published 2016 Jul 1. doi:10.1089/can.2016.0009 McPartland JM, Guy GW, Di Marzo V. Care and feeding of the endocannabinoid system: a systematic review of potential clinical interventions that upregulate the endocannabinoid system. PLoS One. 2014;9(3):e89566. Published 2014 Mar 12. doi:10.1371/journal.pone.0089566 Torrence RD, Rojas DC, Troup LJ. Awareness of Emotional Expressions in Cannabis Users: An Event-Related Potential Study. Front Psychol. 2019;10:69. Published 2019 Feb 1. doi:10.3389/fpsyg.2019.00069 Ware MA, Fitzcharles MA, Joseph L, Shir Y. The effects of nabilone on sleep in fibromyalgia: results of a randomized controlled trial. Anesth Analg. 2010;110(2):604-10. Ste-marie PA, Fitzcharles MA, Gamsa A, Ware MA, Shir Y. Association of herbal cannabis use with negative psychosocial parameters in patients with fibromyalgia. Arthritis Care Res (Hoboken). 2012;64(8):1202-8. Walitt B, Klose P, Fitzcharles MA, Phillips T, Häuser W. Cannabinoids for fibromyalgia. Cochrane Database Syst Rev. 2016;7(7):CD011694. Published 2016 Jul 18. doi:10.1002/14651858.CD011694.pub2 Fiz J, Durán M, Capellà D, Carbonell J, Farré M. Cannabis use in patients with fibromyalgia: effect on symptoms relief and health-related quality of life. PLoS One. 2011;6(4):e18440. Published 2011 Apr 21. doi:10.1371/journal.pone.0018440 Benyamina A, Reynaud M. [Therapeutic use of cannabis derivatives]. Rev Prat. 2014;64(2):165-8. Pacula RL, Smart R. Medical Marijuana and Marijuana Legalization. Annu Rev Clin Psychol. 2017;13:397–419. doi:10.1146/annurev-clinpsy-032816-045128 Alsherbiny MA, Li CG. Medicinal Cannabis-Potential Drug Interactions. Medicines (Basel). 2018;6(1):3. Published 2018 Dec 23. doi:10.3390/medicines6010003 Brown JD, Winterstein AG. Potential Adverse Drug Events and Drug-Drug Interactions with Medical and Consumer Cannabidiol (CBD) Use. J Clin Med. 2019;8(7):989. Published 2019 Jul 8. doi:10.3390/jcm8070989 Pacher P, Bátkai S, Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev. 2006;58(3):389–462. doi:10.1124/pr.58.3.2 Additional Reading Benyamina A, Reynaud M. La revue du praticien. 2014 Feb;64(2):165-8. (Article in French. Abstract referenced.) Therapeutic use of cannabis derivatives. Fiz J, et al. PLoS One. 2011 Apr 21;6(4):e18440. Cannabis use in patients with fibromyalgia: effect on symptoms relief and health-related quality of life. Lynch ME, Campbell F. British Journal of clinical pharmacology. 2011 Nov;72(5):735-44. Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials. McPartland JM, Guy GW, Di Marzo V. PLoS One. 2014 Mar 12;9(3):e89566. Care and feeding of the endocannabinoid system: a systematic review of potential clinical interventions that up regulate the endocannabinoid system. McPartland JM. Journal of bodywork and movement therapies. 2008 Apr;12(2):169-82. Expression of the endocannabinoid system in fibroblasts and myofascial tissues. Russo EB. Neuro endocrinology letters. 2004 Feb-Apr;25(1-2):31-9. Clinical endocannabinoid deficiency (CECD): can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions? Smith SC, Wagner MS. Neuor endocrinology letters. 2014;35(3):198-201. Clinical endocannabinoid deficiency (CEC D) revisited: can this concept explain the therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions? Ste-Marie PA, et al. Arthritis care and research. 2012 Aug;64(8):1202-8. Association of herbal cannabis use with negative psychosocial parameters in patients with fibromyalgia. Ware MA, et al. Anesthesia and analgesia. 2010 Feb 1;110(2):604-10. The effects of nabilone on sleep in fibromyalgia: results of a randomized controlled trial. By Adrienne Dellwo Adrienne Dellwo is an experienced journalist who was diagnosed with fibromyalgia and has written extensively on the topic. See Our Editorial Process Meet Our Medical Expert Board Share Feedback Was this page helpful? Thanks for your feedback! What is your feedback? Other Helpful Report an Error Submit